<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959451</url>
  </required_header>
  <id_info>
    <org_study_id>MucT001-13</org_study_id>
    <nct_id>NCT01959451</nct_id>
  </id_info>
  <brief_title>Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial</brief_title>
  <acronym>TROPICAL-ACS</acronym>
  <official_title>Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether a platelet function testing guided approach with a
      short-term (1 week) prasugrel treatment and a switch over to clopidogrel treatment in
      adequate responders to clopidogrel is non-inferior regarding the combined incidence of
      bleeding and thrombotic complications to a 12 month standard treatment with prasugrel in
      acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention
      (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering of heart attack have highly activated blood platelets. During and after
      invasive treatment of blocked coronary vessels (percutaneous coronary intervention = PCI) a
      potent platelet inhibition is needed to reduce the risk of thrombotic complications which is
      particularly high within the first week after PCI. On the other hand, the use of potent
      platelet inhibitors such as prasugrel is associated with higher bleeding risk particularly
      when used at long-term.  A combination of a potent antiplatelet drug (prasugrel) within the
      first week with a less potent antiplatelet drug (clopidogrel) thereafter might lead to a
      higher net clinical benefit - means less bleeding and thrombotic complications. This
      hypothesis is being investigated in the current trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding events BARC class ≥2</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>economic impact of a platelet function testing guided tailored treatment for ACS patients</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 5 mg or 10mg daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel/Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>see Arm description</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Prasugrel/Clopidogrel</arm_group_label>
    <other_name>Iscover</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Troponin positive ACS

          -  Successful PCI (defined as a post PCI diameter stenosis &lt;20% and TIMI flow ≥2)

          -  A planned treatment of Prasugrel for 12 months after the procedure

          -  written informed consent

        Exclusion Criteria:

          -  Age &lt;18 years and &gt;80 years

          -  Subjects with known contraindications to Clopidogrel treatment, which are
             hypersensitivity to the drug substance or any component of the product and active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage

          -  Subjects with known contraindications to Prasugrel treatment, which are
             hypersensitivity to the drug substance or any component of the product, active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history
             of prior transient ischemic attack (TIA) or stroke

          -  Cardiogenic shock

          -  Subjects requiring concomitant treatment with an anticoagulant agent (Vitamin-K
             antagonists or novel oral anticoagulants such as Rivaroxaban, Dabigatran or Apixaban)

          -  Indication for major surgery (per decision of the treating physician) for the planned
             duration of the study

          -  Simultaneous participation in another clinical trial or participation in any clinical
             trial involving administration of an investigational medicinal product within 30 days
             prior to clinical trial beginning

          -  Known or persistent abuse of medication, drugs or alcohol

          -  Current or planned pregnancy or nursing women, women 90 days after childbirth.
             Females of childbearing potential, who do not use and are not willing to use
             medically reliable methods of contraception for the entire study duration (such as
             oral, injectable, or implantable contraceptives, or intrauterine contraceptive
             devices) unless they are surgically sterilized / hysterectomized or there are any
             other criteria considered sufficiently reliable by the investigator in individual
             cases

          -  Evidence of significant active neuropsychiatric disease, in the investigator's
             opinion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Sibbing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Clinic, Campus Innenstadt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Clinic, Campus Grosshadern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Munich University Clinic, Campus Grosshadern and Innenstadt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Sibbing, MD</last_name>
    <phone>+49 89 5160</phone>
    <phone_ext>2266</phone_ext>
    <email>dirk.sibbing@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julinda Mehilli, MD</last_name>
    <phone>+49 89 7095</phone>
    <phone_ext>3053</phone_ext>
    <email>julinda.mehilli@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <email>franz-josef.neumann@universitaets-herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Dietmar Trenk, MD</last_name>
      <email>Dietmar.Trenk@universitaets-herzzentrum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dieter Trenk</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Josef Hospital im Katholischen Klinikum Bochum Department of Cardiology</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Mügge, MD</last_name>
      <email>a.muegge@klinikum-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Kara Kaffer, MD</last_name>
      <email>k.kara@klinikum-bochum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Mügge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kara Kaffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center at the University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudius Jacobshagen, MD</last_name>
      <email>jacobshagen@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Claudius Jacobshagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz, Department of Cardiology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasso Gori, MD</last_name>
      <email>Tommaso.Gori@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Tommaso Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munich University Clinic, Campus Innenstadt</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Sibbing, MD</last_name>
      <phone>+49 89 5160</phone>
      <phone_ext>2266</phone_ext>
      <email>dirk.sibbing@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Monika Baylacher</last_name>
      <phone>+49 89 5160</phone>
      <phone_ext>7670</phone_ext>
      <email>Monika.Baylacher@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Sibbing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munich University Clinic, Campus Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julinda Mehilli, MD</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>3053</phone_ext>
      <email>julinda.mehilli@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Martina Schulz</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>3064</phone_ext>
      <email>martina.schulz@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Julinda Mehilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Orban, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Rieber, MD</last_name>
      <email>Johannes.Rieber@klinikum-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Rieber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Tuebingen, Department of Cardiology and Cardiovascular Medicine</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Geisler, MD</last_name>
      <email>tobias.geisler@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Geisler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred</name>
      <address>
        <city>Budapest</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Aradi, MD</last_name>
      <phone>+36302355639</phone>
      <email>daniel_aradi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Aradi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prasugrel</keyword>
  <keyword>Clopidogrel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
